Dmitriy Ovcharenko

Dmitriy Ovcharenko

  Dmitriy Ovcharenko, CEO at Altogen Labs (Austin, TX)

  ovcharenko linkedin Dmitriy Ovcharenko,CEO Austin TX Дмитрий Овчаренко, Остин Техас США

Dmitriy Ovcharenko is a founder and CEO of Altogen Labs (since 2008), a GLP-compliant contract research organization (CRO) in Austin,Texas providing pre-clinical research services, pharmacology/toxicology studies, bioremediation, cell banking, gene silencing and RNA interference (RNAi) products and services. Previously, Dmitriy Ovcharenko worked as research scientist at following organizations: Lawrence Berkeley National Laboratory (Edward M Rubin Lab), Ambion/Invitrogen (David Brown Lab), Asuragen (Matt Winkler), and Terapio (Curt Bilby). Dmitriy is a cell and molecular biologist by training, holding degrees in biology, ecology, pharmacology and toxicology, expert in RNAi and bioremediation. Dmitriy performed undergraduate and graduate studies at Novosibirsk State University (1996-2000, 2000-2002) and conducted his doctoral work at University of Texas at Austin (2004-2008). Dmitriy's main research insterest is anticancer therapeutical application of RNAi, including microRNA - small molecules that regulate gene expression of networks of oncogenes. Therapeutical application of microRNA and siRNA oligonucleotides (a part of recently-discovered RNAi phemomena with 2006 Nobel Prize in Physiology & Medicine) holds promise for generation of novel gene-targeted medicines against many uncurable diseases. Dmitriy is a member of the following professional organizations: American Association for Cancer Research, American Society for Pharmacology & Experimental Therapeutics, American Society for Cell Biology, and affiliated with following research journals: Cancer Research Journal, Nucleic Acid Research, and Gene Therapy Journal.

Publications:

1. Dmitriy Ovcharenko, Friedrich Stölzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Gerhard Ehninger, David Brown, Thomas Illmer. miR-10a overexpression is associated with NPM1 mutations and Mdm4 downregulation in intermediate-risk acute myeloid leukemia. Experimental Hematology, 39(10):1030-1042 (2011)

2. Dario Boffelli, Jon McAuliffe, Dmitriy Ovcharenko, Keith D. Lewis, I. Ovcharenko, Lior Pachter, Edward Rubin. Phylogenetic Shadowing of Primate Sequences to Find Functional Regions of the Human Genome. Science 299, (5611): p.1391-1394 (2003)

3. Dmitriy Ovcharenko, Kevin Kelnar, Charles Johnson, Nan Leng, David Brown. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Research 67(22):10782-10788 (2007)

4. Abdulgader Baoum, Dmitriy Ovcharenko, Cory Berkland. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. International Journal of Pharmaceutics 427(1):134-142 (2012)

5. Dmitriy Ovcharenko, Richard Jarvis, Scott Hunicke-Smith, Kevin Kelnar, David Brown. High-throughput RNAi screening in vitro: From cell lines to primary cells. RNA 11: p.985-993 (2005)

6. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Research 67(16):7713-7722 (2007)

7. Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A. MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood, 118(7):1899-1902 (2011)

8. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP. Neutrophil gelatinase associated lipocalin as a survival factor. Biochemical Journal, 391:441-448 (2005)

9. Sachse C., Krausz E., Kronke A., Hannus M., Walsh A., Grabner A., Dmitriy Ovcharenko, Dorris D., Trudel C., Sonnichsen B., Echeverri C. High throughput RNAi strategies for target discovery and validation by using synthetic siRNAs: functional genomics investigations of biological pathways.  Methods in Enzymology 392: p.242-277 (2005)

10. Gabriela Loots, Michaela Kneissel, Hansjoerg Keller, Myma Baptist, Jessie Chang, Nicole  Collette, Dmitriy Ovcharenko, Ingrid Plajzer-Frick, Edward Rubin. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Research 15: p.928-935 (2005)

11. Sirotkin A, Ovcharenko D, Benco A, Mlyncek M. Protein kinases controlling PCNA and p53 expression in human ovarian cells. Funct Integr Genomics 9:185-195 (2009)

12. Sirotkin AV, Lauková M, Ovcharenko D, Brenaut P, Mlyncek M. Identification of microRNAs controlling human ovarian cell proliferation and apoptosis. Journal of Cell Physiology 223:49-56 (2010)

13. Sirotkin AV, Ovcharenko D, Grossmann R, Laukova M, Mlyncek M. Identification of microRNAs controlling human ovarian cell steroidogenesis via a genome-scale screen. Journal of Cell Physiology 219:415-20 (2009)

14. Sirotkin AV, Ovcharenko D, Mlyncek M. Identification of protein kinases that control ovarian hormone release by selective siRNAs. Journal of Molecular Endocrinology 44:45-53 (2010)

Patents:

1. Dmitriy Ovcharenko et al. Methods and compositions involving miRNA and miRNA inhibitor molecules. USA patent number #7,960,359 (2011)

2. Dmitriy Ovcharenko. miR-10 regulated genes and pathways as targets for therapeutic intervention. USA patent number 12,340,329 (2010)

3. Dmitriy Ovcharenko et al. Methods and compositions involving miRNA and miRNA inhibitor molecules. USA patent 11,837,490 (2010)

4. Dmitriy Ovcharenko et al. System and method for electroporating a sample. USA patent number 7,393,681 (2008)

5. Dmitriy Ovcharenko et al. MicroRNAs Differentially expressed in leukemia and uses thereof. USA patent 11,953,606 (2007)

6. Dmitriy Ovcharenko et al. System and method for electroporating a sample. USA patent number 6,897,069 (2005)

Selected Conference Presentations:

1. Dmitriy Ovcharenko. Role of microRNAs in human acute myeloid leukemia (AML). American Association for Cancer Research (2007)

2. Dmitriy Ovcharenko. High throughput in vitro RNAi screening: From cell lines to primary cells. AACR 96th Annual Meeting, Cellular and Molecular Biology Symposium, Anaheim, CA (2005)

3. Dmitriy Ovcharenko, Richard Jarvis. High Throughput In Vitro RNAi Screening: From Cell Lines To Primary Cells. Twelfth International Symposium on Recent Advances in Drug Delivery Systems (2005)

4. Dmitriy Ovcharenko, Thomas Illmer, Jeffrey Shelton, Emmanuel Labourier, David Brown. Expression profiling and functional studies reveal a potential role for microRNAs in human acute myeloid leukemia. The American Society of Cell Biology, San Francisco, CA (2005)

5. Dmitriy Ovcharenko, Kevin Kelnar, Angie Cheng, David Wang, Lance Ford. The use of miRNA and siRNA libraries to identify genes involved in the regulation of hTERT transcription. The American Society of Cell Biology, San Francisco, CA (2005)

6. Dmitriy Ovcharenko. High throughput in vitro RNAi screening: From cell lines to primary cells. Experimental Biology (FASEB),San Diego, CA (2005)

7. Dmitriy Ovcharenko, Richard Jarvis. High Throughput In Vitro RNAi Screening: From Cell Lines To Primary Cells. Twelfth International Symposium on Recent Advances in Drug Delivery Systems (2005)

8. Dmitriy Ovcharenko, Kevin Kelnar, Richard Jarvis. Efficient Delivery of siRNA to Primary Cells and Hard-to-Transfect Cell lines. Gene Delivery 3rd Annual International Conference (2003)

Trade Journal Publications:

1. Ovcharenko D. et al. Effective delivery of functional siRNAs into cells. Pharmaceutical Discovery, Current Applications in RNAi, p.21-26 (2005)

2. Ovcharenko D. et al. High throughput siRNA delivery in vitro: From cell lines to primary cells. Ambion TechNotes 12,(2): p.11-13 (2005)

3. Ovcharenko D. et al. High throughput siRNA electroporation. Ambion TechNotes 12,(1):p.14-15 (2005)

4. Ovcharenko D. et al. Deliver siRNAs into primary cells. Ambion TechNotes 12,(1):p.16-17 (2005)

5. Brown D. et al. Precursor miRNAs for successful miRNA functional studies. Ambion TechNotes 12,(1):p. 3-5 (2005)

6. Beauchamp L. et al. Got small RNA? Ambion TechNotes 12,(1):p.6-7 (2005)

7. Ovcharenko D. et al. Delivering siRNAs to difficult cell types. Ambion TechNotes 11,(3):p. 14-15 (2004)

8. Ovcharenko D. et al. Efficient delivery of siRNAs to human primary cells. Ambion TechNotes 10,(5):p.15-16 (2003)

Links:

Mechanism of RNA Interference: RNAi, Cell biology 4D animation: The Inner Life of a Cell, PBS describes biology of RNAi and medical applications: NOVA scienceNOW RNAi, microRNA and cancer therapeutics website: microRNA.ws

Contact e-mail:

dmitriy(at)ovcharenko-nsk.com

 

What is RNA Interference (RNAi), siRNA, and microRNA:

RNA interference (RNAi), a form of post-transcriptional gene silencing induced by introduction of double-stranded RNA (dsRNA), has become a powerful experimental tool for studying gene function. The RNAi phenomenon was first discovered in Caenorhabditis elegans and is characterized by sequence-specific gene silencing elicited by introduction of dsRNA (Fire et al. 1998; Elbashir et al. 2001) complementary to a target mRNA. In the endogenous RNAi pathway, long dsRNA is cleaved by the RNase III type endonuclease, Dicer, to produce 21–23 base pair (bp) short interfering RNAs. The siRNAs are in turn unwound and incorporated into a multiprotein complex known as the RNA-induced silencing complex (RISC), generating a sequence-specific nuclease that guides the cleavage of specific complementary mRNAs. In mammalian cells, direct introduction of siRNAs is used to experimentally initiate RNAi, because introduction of long dsRNA induces a potent antiviral response in addition to RNAi.
 
MicroRNAs (miRNAs) are small RNA molecules encoded in the genomes of plants and animals. These newly identified molecules are highly conserved RNAs, up to 22 nucleotides in length, that regulate the expression of genes by binding to the 3'-untranslated regions (3'-UTR) of specific mRNAs. Recent studies of miRNA expression implicate miRNAs in brain development, chronic lymphocytic leukemia, colonic adenocarcinoma, Burkitt’s Lymphoma, and viral infection suggesting possible links between miRNAs and viral disease, neurodevelopment, and cancer. Application of microRNAs as therapeutic targets represent a novel molecular based approach for developing new medicines. While siRNA molecules can target only a single gene for disease treatment, microRNA-based therapeutics will have an advantage of a single microRNA targeting a network of genes with minimal off-target side effects, since miRNAs are naturally expressed in human cells.
 

ovcharenko RNAi

RNAi has been rapidly adopted for functional genomics, pathway analysis, and drug target validation experiments, and is now being used in high-throughput experiments with large numbers of siRNAs, or siRNA libraries.
 
A key to all successful siRNA experiments is efficient delivery of the siRNA into cells and subsequent uptake of the siRNA by the RISC. RNAi can be successfully elicited in mammalian cells using exogenously derived siRNA only when the correct method and matrix of delivery conditions are employed for the cell type being used.
 
 

ovcgarenko microRNA

There are several hundreds of known microRNAs, some of which are known to play important regulatory roles in animals by targeting the messages of protein-coding genes for translational repression. Misregulation of miRNA expression has an important role in development of many diseases. Although the first work on miRNA appeared in 1993, only in the last few years has the diversity of this class of small, regulatory RNAs been appreciated.
 
One miRNA can regulate from a few to hundreds of genes, and since over 1,000 miRNA genes are present in higher eukaryotes, the regulatory gene network is important in various cellular functions. Several research groups have provided evidence that miRNAs regulate such cellular processes as early development, cell proliferation and death, apoptosis and fat metabolism, and cell differentiation.

Dmitriy Ovcharenko, CEO Austin Texas, Science Biology RNAi Expert, Дмитрий Овчаренко Остин Техас США